Total debt climbed from $5.7M in Q2 2025 to $1.2B in Q3 2026 and debt-to-equity rose to 1.20, while cash fell to $56.0M, indicating that acquisition-driven leverage now dominates a thinner liquidity cushion.
Ligand Pharmaceuticals Incorporated (LGND) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 608.23M | 832.27M | 331.56M | 237.43M | 263.6M | 464.75M | 500.56M | 1.12B | 870.54M | 237.02M | 163.05M | 215.57M | 185.16M | 24.88M | 23.82M | 32.23M | 37.02M | 68.17M | 93.93M | 109.94M | 235.56M | 132.97M | 172.82M | 130.16M | 83.75M | 53.57M | 44.65M | 56.7M | 78M | 84.1M | 85.4M |
| Cash & Short-Term Investments | 447.39M | 733.52M | 256.17M | 170.31M | 211.87M | 341.11M | 411.19M | 1.07B | 764.57M | 201.66M | 141.05M | 200.22M | 167.34M | 15.98M | 12.38M | 17.04M | 22.7M | 53.23M | 80.67M | 94.41M | 171.85M | 86.93M | 112.49M | 99.03M | 64.25M | 37.69M | 23.66M | 47.2M | 32.8M | 62.3M | 34.8M |
| Cash Only | 55.96M | 174.93M | 72.31M | 22.95M | 45.01M | 19.52M | 47.62M | 71.54M | 718.38M | 201.66M | 141.05M | 200.22M | 167.34M | 15.98M | 12.38M | 7.04M | 3.35M | 16.03M | 28.75M | 76.81M | 158.4M | 66.76M | 92.31M | 59.03M | 42.42M | 20.74M | 9.22M | 29.9M | 32.8M | 62.3M | 34.8M |
| Short-Term Investments | 391.44M | 558.59M | 183.86M | 147.35M | 166.86M | 321.59M | 363.57M | 998.32M | 46.19M | 0 | 0 | 0 | 0 | 0 | 0 | 10M | 19.35M | 37.2M | 51.92M | 17.6M | 13.45M | 20.17M | 20.18M | 40M | 21.82M | 16.95M | 14.44M | 17.3M | 0 | 0 | 0 |
| Accounts Receivable | 107.52M | 61.05M | 42.45M | 39.31M | 35.04M | 91.65M | 59.06M | 41.75M | 55.85M | 25.6M | 18.22M | 11.68M | 13.64M | 6.72M | 8.94M | 12.43M | 13.74M | 10.4M | 12.1M | 14.3M | 15.59M | 20.95M | 30.85M | 19.05M | 7.36M | 9.8M | 12.82M | 1.7M | 0 | 0 | 3.1M |
| Days Sales Outstanding | 105.43 | 83.12 | 92.7 | 109.27 | 65.17 | 138.49 | 131.81 | 126.69 | 81.07 | 66.21 | 61.02 | 59.3 | 77.15 | 50.11 | 103.98 | 151.09 | 213.13 | 97.48 | 161.69 | 404.91 | 40.36 | 43.31 | 68.86 | 49.27 | 27.78 | 46.85 | 97.29 | 15.17 | - | - | 30.75 |
| Inventory | 14.51M | 9.13M | 14.11M | 23.97M | 13.29M | 27.33M | 26.49M | 7.3M | 7.12M | 4.37M | 1.92M | 1.63M | 269K | 1.39M | 1.7M | 1.3M | -22.7M | -53.23M | 1.15M | -10.47M | 3.86M | 9.33M | 11.77M | 8.26M | 4.84M | 3.76M | 5.65M | 5.7M | 6.2M | 0 | 0 |
| Days Inventory Outstanding | -238.43 | 505.65 | 465.2 | 249.61 | 91.85 | 160.42 | 317.82 | 234.69 | 410.33 | 297.46 | 125.99 | 102.64 | 10.75 | 88.62 | 172.01 | 96.73 | - | - | - | - | 62.16 | 85.49 | 107.95 | 95.38 | 87.02 | 98.3 | 1.27K | 671.13 | -293.9 | - | - |
| Other Current Assets | 38.81M | 28.58M | 16.9M | 2.66M | 2.27M | 4.67M | 3.82M | 4.73M | 89.19M | 5.39M | 0 | 0 | 4.08M | 0 | 2K | 237K | 5.29M | 4.53M | 11K | 5.07M | 42.82M | 15.75M | 17.71M | 3.81M | 7.31M | 2.33M | 2.51M | 2.1M | 39M | 21.8M | 47.5M |
| Total Non-Current Assets | 1.63B | 728.37M | 610.22M | 549.79M | 499.07M | 832.84M | 861.73M | 371.27M | 390.26M | 434M | 438.53M | 318.36M | 72.87M | 79.83M | 80.44M | 90.12M | 38.54M | 45.53M | 77.52M | 63.34M | 90.5M | 181.65M | 159.64M | 171.1M | 186.86M | 63.9M | 68.77M | 77.9M | 78M | 23.3M | 16.7M |
| Property, Plant & Equipment | 24.22M | 10.79M | 24.81M | 25.06M | 27.49M | 32.6M | 37.17M | 17.62M | 5.37M | 4.21M | 1.82M | 372K | 486K | 867K | 788K | 455K | 559K | 8.52M | 12.9M | 2.87M | 5.55M | 22.48M | 23.65M | 23.5M | 9.67M | 9.69M | 10.97M | 20.5M | 23.7M | 14.9M | 11.7M |
| Fixed Asset Turnover | 19.63x | 24.84x | 6.74x | 5.24x | 7.14x | 7.41x | 4.40x | 6.83x | 46.81x | 33.50x | 59.91x | 193.32x | 132.79x | 56.49x | 39.83x | 66.02x | 42.11x | 4.57x | 2.12x | 4.50x | 25.39x | 7.86x | 6.91x | 6.01x | 9.99x | 7.88x | 4.38x | 2.00x | 0.75x | 3.47x | 3.15x |
| Goodwill | 207.86M | 101.54M | 105.25M | 103.37M | 105.67M | 105.67M | 189.66M | 95.23M | 306.44M | 314.54M | 276.91M | 60.59M | 62.96M | 65.34M | 12.24M | 14.89M | 0 | 0 | 5.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 302.04M | 422.31M | 266.65M | 299.61M | 352.64M | 386.8M | 606.31M | 230.54M | 31.46M | 19.53M | 25.82M | 8.55M | 4.57M | 4.57M | 55.91M | 57.44M | 12.95M | 2.52M | 0 | 0 | 83.08M | 146.77M | 127.44M | 137.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 616.19M | 183.58M | 10.91M | 111.61M | 3M | 0 | 0 | 0 | 601.22M | 6.44M | 8.35M | 29.73M | -257K | 5.84M | 8.2M | 1.34M | 1.34M | 1.46M | 0 | 0 | 0 | 0 | 0 | -250.12M | 18.05M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 848.07M | 1.79M | 202.53M | 9.92M | 1.74M | 272.03M | 4.27M | 2.27M | -600.75M | 4.86M | 1.74M | 2.55M | 4.86M | 1.64M | 3.29M | 15.76M | 23.32M | 7.97M | 59.24M | 60.47M | 1.86M | 12.4M | 8.55M | 9.74M | 159.13M | 54.21M | 57.8M | 57.4M | 54.3M | 8.4M | 5M |
| Total Assets | 2.24B | 1.56B | 941.77M | 787.22M | 762.67M | 1.3B | 1.36B | 1.49B | 1.26B | 671.02M | 601.59M | 533.93M | 258.03M | 104.71M | 104.26M | 122.35M | 75.56M | 113.7M | 171.45M | 173.28M | 326.05M | 314.62M | 332.47M | 301.25M | 270.61M | 117.47M | 113.42M | 134.6M | 156M | 107.4M | 102.1M |
| Asset Turnover | 0.14x | 0.17x | 0.18x | 0.17x | 0.26x | 0.19x | 0.12x | 0.08x | 0.20x | 0.21x | 0.18x | 0.13x | 0.25x | 0.47x | 0.30x | 0.25x | 0.31x | 0.34x | 0.16x | 0.07x | 0.43x | 0.56x | 0.49x | 0.47x | 0.36x | 0.65x | 0.42x | 0.30x | 0.11x | 0.48x | 0.36x |
| Asset Growth % | 316.87% | 65.71% | 19.63% | 3.22% | -41.22% | -4.75% | -8.87% | 18.57% | 87.89% | 11.54% | 12.67% | 106.93% | 146.42% | 0.43% | -14.79% | 61.93% | -33.54% | -33.68% | -1.06% | -46.86% | 3.63% | -5.37% | 10.36% | 11.32% | 130.36% | 3.57% | -15.73% | -13.72% | 45.25% | 5.19% | 9.08% |
| Total Current Liabilities | 500.57M | 37.45M | 37.11M | 16.78M | 98.81M | 41.66M | 100.11M | 17M | 82.25M | 238.87M | 227.13M | 20.84M | 22.78M | 28.94M | 35.44M | 43.64M | 35.63M | 52.17M | 70.61M | 50.97M | 170.81M | 235.21M | 216.71M | 54.05M | 30.54M | 31.73M | 28.41M | 20.7M | 26.9M | 21.7M | 13.8M |
| Accounts Payable | 4.09M | 3.24M | 5.23M | 2.43M | 5.31M | 8.4M | 3.78M | 2.42M | 4.18M | 2.26M | 2.73M | 4.08M | 7.7M | 3.95M | 5.85M | 11.06M | 8.6M | 16.95M | 14.63M | 12.68M | 12.26M | 15.36M | 17.35M | 18.84M | 11.98M | 5.38M | 3.83M | 5.4M | 12.4M | 10.7M | 4.1M |
| Days Payables Outstanding | -111.23 | 179.41 | 172.48 | 25.27 | 36.67 | 49.33 | 45.4 | 77.84 | 240.93 | 153.66 | 179.13 | 256.64 | 307.55 | 251.55 | 593.37 | 822.72 | - | 405.97 | - | - | 197.62 | 140.7 | 159.12 | 217.5 | 215.32 | 140.93 | 863.32 | 635.81 | -587.79 | -398.52 | -159.2 |
| Short-Term Debt | 448.31M | 0 | 0 | 0 | 76.69M | 0 | 0 | 0 | 26.43M | 224.53M | 212.91M | 201.99M | 334K | 9.11M | 14.84M | 16.2M | 8.03M | 0 | 1.83M | 1.53M | 37.75M | 2.75M | 2.92M | 2.48M | 2.09M | 5.37M | 3.48M | 4.1M | 3.2M | 2.8M | 2.6M |
| Deferred Revenue (Current) | 1.86M | 621K | 1.9M | 1.84M | 976K | 654K | 29.43M | 2.14M | 3.29M | 173K | 0 | -934K | 150K | 116K | 486K | 1.24M | 1.7M | 6.69M | 12.27M | 1.96M | 59.95M | 157.52M | 152.53M | 2.56M | 4.68M | 8.73M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 43.61M | 6.81M | -3.2M | 4.94M | 6.26M | 22.57M | 49.38M | 7.62M | 44.3M | 1.41M | 5.09M | 15.04M | 12.63M | 12.26M | 10.88M | 13.34M | 5.3M | 14.18M | 18.72M | 10.47M | 14.35M | 0 | 0 | -105.66M | -4.82M | 0 | 21.11M | 11.2M | 11.3M | 8.2M | 7.1M |
| Current Ratio | 1.22x | 22.23x | 8.93x | 14.15x | 2.67x | 11.15x | 5.00x | 66.09x | 10.58x | 0.99x | 0.72x | 10.35x | 8.13x | 0.86x | 0.67x | 0.74x | 1.04x | 1.31x | 1.33x | 2.16x | 1.38x | 0.57x | 0.80x | 2.41x | 2.74x | 1.69x | 1.57x | 2.74x | 2.90x | 3.88x | 6.19x |
| Quick Ratio | 1.19x | 21.98x | 8.55x | 12.72x | 2.53x | 10.50x | 4.74x | 65.66x | 10.50x | 0.97x | 0.71x | 10.27x | 8.12x | 0.81x | 0.62x | 0.71x | 1.68x | 2.33x | 1.31x | 2.36x | 1.36x | 0.53x | 0.74x | 2.26x | 2.58x | 1.57x | 1.37x | 2.46x | 2.67x | 3.88x | 6.19x |
| Cash Conversion Cycle | -21.77 | 409.36 | 385.42 | 333.61 | 120.35 | 249.57 | 404.22 | 283.53 | 250.47 | 210.01 | 7.89 | -94.7 | -219.65 | -112.81 | -317.37 | -574.89 | - | - | - | - | -95.1 | -11.9 | 17.69 | -72.86 | -100.52 | 4.21 | 508.76 | 50.49 | - | - | - |
| Total Non-Current Liabilities | 775.13M | 505.98M | 74.22M | 69.52M | 66.37M | 434.77M | 552.65M | 710.68M | 617.64M | 13.51M | 3.6M | 208.7M | 210.84M | 26.16M | 42.34M | 70.06M | 46.92M | 57.78M | 111.2M | 93.19M | 127.89M | 189.83M | 191.07M | 176.48M | 166.06M | 143.62M | 140.13M | 139.5M | 140.5M | 51.4M | 53.8M |
| Long-Term Debt | 679.91M | 446.19M | 0 | 0 | 0 | 320.72M | 442.29M | 638.96M | 609.86M | 18.86M | 29.56M | 205.37M | 195.91M | 0 | 13.44M | 35.54M | 22.85M | 30.99M | 47.52M | 627K | 0 | 166.75M | 167.09M | 167.41M | 155.25M | 136.76M | 131.71M | 136.7M | 90.5M | 51.4M | 54M |
| Capital Lease Obligations | 33.41M | 4.2M | 5.82M | 5.75M | 10.34M | 2.26M | 5.64M | 9.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.28M | 2.18M | 0 | 2.16M | 3.43M | 4M | 2.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 119.27M | 52.61M | 32.52M | 31.62M | 30.61M | 30.86M | 64.6M | 32.94M | 51.97M | -22.38M | -357K | 0 | 2.79M | 1.1M | 725K | 2.52M | 372K | 0 | -16.82M | 0 | -2.55M | -4.2M | -4.51M | 9.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 51.39M | 2.97M | 35.88M | 17M | 25.38M | 80.94M | 40.12M | 28.82M | 7.78M | -8.88M | -25.96M | 3.33M | 10.06M | 22.98M | 25.8M | 28.53M | 21.15M | 16.31M | 21.39M | 92.57M | 125.73M | 19.65M | 15.47M | 6.43M | 10.81M | 6.86M | 8.43M | 2.8M | 50M | 0 | -200K |
| Total Liabilities | 1.28B | 543.42M | 111.33M | 86.3M | 165.18M | 476.43M | 652.76M | 727.68M | 699.89M | 252.37M | 230.73M | 229.54M | 233.62M | 55.1M | 77.78M | 113.7M | 82.55M | 109.95M | 181.81M | 144.16M | 298.7M | 425.04M | 407.78M | 230.53M | 196.59M | 175.35M | 168.55M | 160.2M | 167.4M | 73.1M | 67.6M |
| Total Debt | 1.15B | 451.49M | 7.11M | 6.17M | 87.75M | 324.39M | 456.41M | 650.18M | 636.3M | 224.53M | 212.91M | 205.37M | 196.24M | 9.11M | 28.28M | 51.74M | 30.89M | 40.87M | 4.01M | 2.15M | 39.91M | 172.92M | 174.02M | 172.53M | 157.34M | 142.13M | 135.18M | 140.8M | 93.7M | 54.2M | 56.6M |
| Net Debt | 1.1B | 276.56M | -65.2M | -16.79M | 42.74M | 304.86M | 408.8M | 578.64M | -82.08M | 22.87M | 71.86M | 5.15M | 28.91M | -6.87M | 15.9M | 44.7M | 27.54M | 24.83M | -24.75M | -74.66M | -118.5M | 106.16M | 81.71M | 113.5M | 114.91M | 121.38M | 125.96M | 110.9M | 60.9M | -8.1M | 21.8M |
| Debt / Equity | 1.20x | 0.44x | 0.01x | 0.01x | 0.15x | 0.40x | 0.64x | 0.85x | 1.13x | 0.54x | 0.57x | 0.67x | 8.04x | 0.18x | 1.07x | 5.98x | - | 10.92x | - | 0.07x | 1.46x | - | - | 2.44x | 2.13x | - | - | - | - | 1.58x | 1.64x |
| Debt / EBITDA | 41.28x | 5.58x | 0.56x | 0.13x | 1.89x | 2.10x | 6.97x | 0.76x | 3.57x | 2.81x | 3.86x | 6.86x | 8.81x | 0.52x | 8.57x | 24.73x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 39.28x | 3.42x | -5.16x | -0.35x | 0.92x | 1.97x | 6.24x | 0.68x | -0.46x | 0.29x | 1.30x | 0.17x | 1.30x | -0.39x | 4.82x | 21.37x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 10.32x | 33.71x | 1.83x | 98.04x | 21.02x | 4.68x | 1.05x | 23.29x | 4.59x | 6.02x | 1.71x | 2.32x | 4.26x | 7.70x | 0.37x | 0.10x | -264.57x | -35.56x | -481.75x | -71.73x | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 961.76M | 1.02B | 830.44M | 700.91M | 597.49M | 821.16M | 709.52M | 767.23M | 560.91M | 418.65M | 370.85M | 304.39M | 24.41M | 49.61M | 26.48M | 8.65M | -6.99M | 3.74M | -10.37M | 29.11M | 27.35M | -110.42M | -75.32M | 70.73M | 74.02M | -57.88M | -55.13M | -25.6M | -11.4M | 34.3M | 34.5M |
| Equity Growth % | 65.85% | 22.49% | 18.48% | 17.31% | -27.24% | 15.73% | -7.52% | 36.78% | 33.98% | 12.89% | 21.83% | 1147.1% | -50.8% | 87.32% | 206.33% | 223.67% | -286.73% | 136.12% | -135.6% | 6.45% | 124.77% | -46.61% | -206.49% | -4.44% | 227.89% | -4.99% | -115.33% | -124.56% | -133.24% | -0.58% | 22.78% |
| Book Value per Share | 48.18 | 50.12 | 45.40 | 39.47 | 35.42 | 47.61 | 43.84 | 38.83 | 23.31 | 17.83 | 17.80 | 14.34 | 1.14 | 2.39 | 1.33 | 0.44 | -0.36 | 0.20 | -0.65 | 1.78 | 2.04 | -8.95 | -6.13 | 6.00 | 6.42 | -5.84 | -5.94 | -3.26 | -1.69 | 6.21 | 7.19 |
| Total Shareholders' Equity | 961.76M | 1.02B | 830.44M | 700.91M | 597.49M | 821.16M | 709.52M | 767.23M | 560.91M | 418.65M | 370.85M | 304.39M | 26.32M | 49.61M | 26.48M | 8.65M | -6.99M | 3.74M | -10.37M | 29.11M | 27.35M | -110.42M | -75.32M | 70.73M | 74.02M | -57.88M | -55.13M | -25.6M | -11.4M | 34.3M | 34.5M |
| Common Stock | 20K | 20K | 20K | 18K | 17K | 17K | 16K | 17K | 21K | 21K | 21K | 20K | 20K | 21K | 21K | 21K | 21K | 123K | 119K | 101K | 100K | 73K | 73K | 73K | 72K | 60K | 57K | 100K | 0 | 0 | 0 |
| Retained Earnings | 554.77M | 608.09M | 498.98M | 503.02M | 450.86M | 449.09M | 391.95M | 400.11M | -229.2M | -400.92M | -431.13M | -402.01M | -659.32M | -671.34M | -682.76M | -681.77M | -691.95M | -681.57M | -679.63M | -581.51M | -862.8M | -831.06M | -794.66M | -655.78M | -618.32M | -585.72M | -542.73M | -470.3M | -395.6M | -277.7M | -177.6M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -42.28M | -42.28M | -42.23M | -42.13M | -42.13M | -40.52M | -911K | -911K | -911K | -911K | -911K | -911K | -911K | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.44M | 8.46M | -5.94M | -817K | -984K | -917K | -801K | -216K | -1.02M | 2.49M | 2.74M | 4.9M | 4.95M | 2.91M | -4.88M | 0 | 31K | 513K | 81K | 9K | -481K | 490K | 229K | -66K | -43K | -678K | -2.03M | -4.1M | -17.8M | -14.5M | -11M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LGND stock.
As of 2025, Ligand Pharmaceuticals Incorporated (LGND) had total assets of $1.56B including $832.3M in current assets.
Ligand Pharmaceuticals Incorporated (LGND) carries total debt of $451.5M, offset by $733.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Ligand Pharmaceuticals Incorporated (LGND) has total shareholders' equity (book value) of $1.02B ($50.12 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Ligand Pharmaceuticals Incorporated (LGND) reported a current ratio of 22.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Acquisition-driven balance sheet swing
Metrics are mathematically derived from official filings.
Balance Sheet Rebuilt Through Acquisition Leverage
According to reported quarterly figures, LGND's total assets rose from $948.6M in Q2 2025 to $2.2B in Q3 2026 while total debt climbed from $5.7M to $1.2B, a rapid expansion that reshaped the balance sheet within roughly one year.
The step-change in both assets and debt suggests the company financed a large acquisition largely through borrowing rather than retained earnings, which appears consistent with the $836.3M net acquisition outflow in Q3 2026. Equity grew more modestly, so the expansion is increasingly reliant on lenders, and investors should monitor whether royalty cash flows can service the higher debt load without further strain.
Leverage Rises Sharply After Acquisition Funding
Based on reported figures, LGND's debt-to-equity ratio moved from 0.01 in mid-2025 to 1.20 in Q3 2026, indicating that leverage has become a dominant feature of the capital structure rather than a minor one.
A D/E ratio near 1.2 changes the risk profile of the equity, since interest obligations now compete directly with operating overhead that already consumes much of the gross royalty margin. The figures do not disclose maturity profiles or covenant terms, so refinancing risk cannot be fully assessed from this data alone and warrants further investigation.
Cash Buffer Thins Against Rising Obligations
As reported in financial statements, LGND's cash fell to $56.0M in Q3 2026 from $1.0B in Q2 2026, while the current ratio stood at 1.22, leaving a narrower cushion relative to near-term obligations.
The sharp drawdown in cash after the acquisition implies the balance sheet's liquidity was largely deployed rather than held in reserve, which reduces flexibility to absorb royalty volatility. A current ratio of 1.22 is adequate on paper, yet the swing from very high to thin cash coverage suggests the buffer against shocks has been materially reduced.
Goodwill and Intangibles Drive Asset Base
Per reported figures, goodwill of $207.9M and PPE of only $24.2M in Q3 2026 indicate that LGND's asset base is overwhelmingly intangible, consistent with an asset-light royalty aggregator model.
A small PPE balance alongside a large acquisition-driven asset base confirms that value rests on purchased royalty streams and intellectual property rather than physical plant. This makes asset valuation sensitive to impairment testing, and the gap between the $2.2B asset base and the much smaller tangible base warrants monitoring if royalty performance underperforms acquisition assumptions.
Headline Equity Masks Negative Operating Quarter
Based on the supplied data, LGND's retained earnings of $554.8M and a reported Q3 2026 operating loss of $15.8M suggest that the equity base may look stronger than the most recent operating trend supports.
Retained earnings built up over prior profitable periods can mask a near-term reversal in earnings power, particularly when non-operating items drive reported net income. Investors should consider that the balance sheet's apparent solidity depends partly on historical accumulation rather than current operating momentum, and that the royalty concentration noted in prior analysis could amplify any further decline.